<DOC>
	<DOCNO>NCT02052739</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability SAGE-547 subject super-refractory status epilepticus ( SRSE ) .</brief_summary>
	<brief_title>Study Evaluate SAGE-547 Injection Adjunctive Therapy Treatment Super-Refractory Status Epilepticus</brief_title>
	<detailed_description>This open-label study consist Screening period ( 1 day ) , 4-day treatment period ( 96 hour ) follow 1-day dose taper period ( 24 hour ) , 2-day acute follow-up period , 3 week extend follow-up period . On Day 1 treatment SRSE subject seizure suppression burst-suppression continuous IV AED ( third-line agent ) give 1-hour IV load infusion SAGE-547 follow maintenance infusion . After 48 hour SAGE-547 treatment , continuous IV AED ( third-line agent ) wean continue SAGE-547 maintenance infusion remainder treatment period . After 96 hour ( 4 day ) therapy SAGE-547 , dose taper discontinued 24 hour . The subject routine continuous EEG monitoring Screening period , continue 48 hour SAGE-547 treatment complete . Subjects follow-up examination weekly next 3 week ( Days 8 , 15 , 22 , 29 ) , safety functional assessment obtain . Apart treatment SAGE-547 , subject receive standard care adult SRSE along ongoing treatment underlie medical condition .</detailed_description>
	<mesh_term>Status Epilepticus</mesh_term>
	<criteria>Subjects 2 year age old . Subjects EEGconfirmed SRSE diagnosis concomitant therapy continuous IV AED ( thirdline agent ) â‰¥ 24 hour . For study , SRSE define follow criterion accordance use major epilepsy treatment center : Failure respond administration least one firstline agent ( e.g. , benzodiazepine emergent initial AED treatment ) , accord institution standard care , Failure respond least one secondline agent ( e.g. , phenytoin , fosphenytoin , valproate , phenobarbital , levetiracetam urgent control AED ) accord institution standard care , Presence one breakthrough seizures &gt; 6 hour initiation continuous IV AED/thirdline agent ( e.g. , pentobarbital , midazolam , propofol ) Subjects SRSE due anoxic/hypoxic encephalopathy , child ( subject age less 18 year ) encephalopathy due underlie progressive neurological disorder . Subjects clinically significant electrocardiogram ( ECG ) abnormality . Subjects significant medical surgical condition may compromise vital organ system , condition would place subject increase risk dialysis acute respiratory distress syndrome , severe cardiogenic vasodilatory shock require 2 pressor , fulminant hepatic failure , etc . Subjects receive continuous IV AED ( thirdline agent ) seizure suppression burstsuppression require great 24 hour wean .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Status Epilepticus</keyword>
	<keyword>Refractory status epilepticus</keyword>
	<keyword>Super-refractory status epilepticus</keyword>
	<keyword>SAGE-547</keyword>
	<keyword>SAGE</keyword>
	<keyword>Sage Therapeutics</keyword>
</DOC>